GlassScriptPhysician profile
Anthony J Degenhard
NPI 1790781193
$6,849.48
in general payments reported to CMS, 2019-2025
38 companies · $670 in 2025
The $670 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,267 · 2020: $1,198 · 2021: $881 · 2022: $1,032 · 2023: $989 · 2024: $813 · 2025: $670.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,347 · Education: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,347.12 |
| Education | $124.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $884.74 | 2019-2024 | Xarelto |
| Amgen INC. | $708.30 | 2019-2025 | Tavneos, Parsabiv, Epogen |
| Otsuka America Pharmaceutical, INC. | $542.61 | 2019-2024 | Jynarque |
| Astrazeneca Pharmaceuticals LP | $469.98 | 2019-2025 | Farxiga, Lokelma |
| Novartis Pharmaceuticals Corporation | $451.09 | 2019-2025 | |
| Aurinia Pharma U.S., INC. | $391.93 | 2021-2025 | Lupkynis |
| Fresenius USA Marketing, INC. | $390.77 | 2020-2025 | Velphoro, Velphoro |
| Daiichi Sankyo INC. | $349.03 | 2019-2025 | Injectafer |
| Mallinckrodt Hospital Products INC. | $271.36 | 2020-2025 | Terlivaz, Acthar |
| Akebia Therapeutics INC | $268.93 | 2019-2024 | Auryxia, Vafseo |
| Opko Pharmaceuticals, LLC | $206.76 | 2019-2024 | Rayaldee |
| Calliditas Therapeutics US INC. | $200.29 | 2022-2025 | Tarpeyo |
| Bayer Healthcare Pharmaceuticals INC. | $179.59 | 2021-2024 | |
| Horizon Therapeutics Plc | $166.64 | 2019-2023 | Krystexxa |
| Mallinckrodt Enterprises LLC | $147.82 | 2019 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Degenhard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.